Probing for peptidic drugs (2-10 kDa) in doping control blood samples.

Thomas, Andreas et al.·Analytical science advances·2022·
RPEP-065382022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

The method successfully detected multiple peptides in blood samples, fulfilling WADA requirements.

Key Numbers

How They Did This

The study employed liquid chromatography coupled with high-resolution mass spectrometry for peptide analysis in blood samples.

Why This Research Matters

This research is significant for improving doping control in sports, ensuring fair competition. It provides a reliable method for detecting banned substances that are increasingly used by athletes.

What This Study Doesn't Tell Us

The study primarily focuses on blood samples and may not address urine testing or other sample types.

Trust & Context

Original Title:
Probing for peptidic drugs (2-10 kDa) in doping control blood samples.
Published In:
Analytical science advances, 3(7-8), 235-243 (2022)
Database ID:
RPEP-06538

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-06538·https://rethinkpeptides.com/research/RPEP-06538

APA

Thomas, Andreas; Thilmany, Sam; Hofmann, Amelie; Thevis, Mario. (2022). Probing for peptidic drugs (2-10 kDa) in doping control blood samples.. Analytical science advances, 3(7-8), 235-243. https://doi.org/10.1002/ansa.202200027

MLA

Thomas, Andreas, et al. "Probing for peptidic drugs (2-10 kDa) in doping control blood samples.." Analytical science advances, 2022. https://doi.org/10.1002/ansa.202200027

RethinkPeptides

RethinkPeptides Research Database. "Probing for peptidic drugs (2-10 kDa) in doping control bloo..." RPEP-06538. Retrieved from https://rethinkpeptides.com/research/thomas-2022-probing-for-peptidic-drugs

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.